My research interest is to understand the mechanism of cancer cell growth and metastasis and explore how epigenetic regulation control gene expression including fetal globin gene silencing in sickle cell disease. We have two areas of research interest:
1) Understand the mechanism of cancer cell growth, invasion and metastasis to identify new target in cancer treatment, particularly focus on prostate cancer and breast cancer. We employ two experimental systems including 2-D or 3-D cultured primary and cancer cell lines, as well as mice models integrated with a number of epigenetic, molecular, and cell biology approaches to pursue in our studies. Expertise includes: Orthotopic mouse models of human prostate cancer and human breast cancer; Experimental metastasis mouse model; Human xenograft tumor mouse model; 3D culture of tumor cell growth and invasion; epigenetic regulation (acetylation, methylation and chromatin immunoprecipitation assays), Chromosome conformation capture (3C) assay.
2) Understand the mechanism of controlling fetal hemoglobin gene expression to identify new targets in the sickle cell disease and thalassemia treatment. We used erythroid progenitor cells or induced pluripotent stem (iPS) cells from sickle cell or thalassemia patients and cord blood, to determine the efficacy of small molecules compounds in fetal hemoglobin induction, and determine the mechanism that control locus control region (LCR) looping and transcription complex formation in LCR and fetal hemoglobin promoter.
- Beijing Medical University, PhD
- Hebei University, MS
- Hebei University, BS
- Published on 8/28/2017
Dai Y, Chen T, Ijaz H, Cho EH, Steinberg MH. SIRT1 activates the expression of fetal hemoglobin genes. Am J Hematol. 2017 Nov; 92(11):1177-1186. PMID: 28776729.
- Published on 11/18/2016
Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan; 92(1):E10-E11. PMID: 27766663.
- Published on 8/8/2016
Cho EH, Dai Y. SIRT1 controls cell proliferation by regulating contact inhibition. Biochem Biophys Res Commun. 2016 Sep 16; 478(2):868-72. PMID: 27514448.
- Published on 12/29/2015
Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP. Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One. 2015; 10(12):e0144660. PMID: 26713848.
- Published on 10/27/2015
Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016 Jan; 56(1):62-9. PMID: 26603726.
- Published on 9/3/2014
Zhu L, Qi J, Chiao CY, Zhang Q, Porco JA, Faller DV, Dai Y. Identification of a novel polyprenylated acylphloroglucinol-derived SIRT1 inhibitor with cancer-specific anti-proliferative and invasion-suppressing activities. Int J Oncol. 2014 Nov; 45(5):2128-36. PMID: 25189993.
- Published on 8/20/2014
Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y. SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res. 2015 Jan; 13(1):41-9. PMID: 25143434.
- Published on 10/4/2012
Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y. SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate. 2013 Apr; 73(5):522-30. PMID: 23038275.
- Published on 1/16/2012
Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012 Oct 25; 31(43):4619-29. PMID: 22249256.
- Published on 12/12/2011
Moore RL, Dai Y, Faller DV. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol. 2012 Apr; 213(1):37-48. PMID: 22159506.
View 10 more publications: View full profile at BUMC